ADMA Biologics (ADMA) Hit With Federal Securities Lawsuit Over Revenue Inflation Allegations
Key takeaways
- ADMA Biologics (ADMA) Hit With Federal Securities Lawsuit Over Revenue Inflation Allegations Faheem Tahir Sun, June 21, 2026 at 3:34 AM GMT+7 2 min read ADMA With an upside potential of 121.45%, ADMA Biologics, Inc.
- On June 10, 2026, Raymond James analyst Ryan Deschner resumed coverage of ADMA Biologics, Inc.
- That bullish call came just days before TheFly reported on June 15, 2026, that ADMA Biologics, Inc.
ADMA Biologics (ADMA) Hit With Federal Securities Lawsuit Over Revenue Inflation Allegations Faheem Tahir Sun, June 21, 2026 at 3:34 AM GMT+7 2 min read ADMA With an upside potential of 121.45%, ADMA Biologics, Inc. (NASDAQ:ADMA) ranks among the stocks under $20 that will explode. The company is navigating a sharp divide between bullish analyst sentiment and mounting legal scrutiny tied to allegations from earlier this year.
On June 10, 2026, Raymond James analyst Ryan Deschner resumed coverage of ADMA Biologics, Inc. (NASDAQ:ADMA) with an “Outperform” rating and a $21 price target. Deschner told investors that ADMA has transformed into a profitable, high-growth company over the past few years, and said its growth is insulated from “Most Favored Nation” policies, tariffs, and Medicare pricing negotiations, given the nature of its plasma-derived programs and its U.S.-based manufacturing and sales.
That bullish call came just days before TheFly reported on June 15, 2026, that ADMA Biologics, Inc. (NASDAQ:ADMA) is facing a federal securities lawsuit.